Laboratory Question for the Week of January 19, 2026
Under what conditions do we report new 2026 code 87494?
Under what conditions do we report new 2026 code 87494?
On the hospital side, during an MAA mapping study, the doctors are using a device called a TriNav catheter to temporarily occlude the vessel. To be clear, they are not performing an embolization at this point. Historically, we have billed for catheterization and imaging, but with the release of the C9797 code, we are now being instructed to bill C9797 during the MAA mapping, even when no true embolization is performed. The patient returns a few weeks later for the Y90 treatment, which also involves the use of the TriNav catheter. At that time, I billed the procedure with C9797. What is the correct way to bill for the MAA mapping session on the hospital side?
If a screening Mammogram (77067) and tomosynthesis (77063) are performed unilaterally, should Modifier 52 be placed on both CPTs®?
Why was code 81354 created in 2026, and when do we report it?
2026 has arrived, and for many coding professionals, the lower extremity revascularization overhaul is quickly shifting from a future concern in 2025 to a day-to-day
Under what circumstances can code 80051 be reported multiple times?
For proper reporting of CTA exams, there is a well-documented list of acceptable 3D techniques to satisfy the code requirement. These are 3D MIP, surface-shaded rendering, and volume rendering, as well as “other 3D techniques.” We’ve come across dictations that state 2D MIPs. Is this a type of 3D technique?
In regard to last week’s question, should a study be initiated but not completed, what modifier would we report with the code?
Can we append modifier 91 for the billing of multiple units of the organ and disease panel codes 80047 and 80048?
A storm of coding and compliance changes will sweep through interventional radiology and radiology, creating challenges for coding and compliance professionals alike. Reimbursement is especially
Can we charge for 78999-“Unlisted miscellaneous procedure, diagnostic nuclear medicine” to reflect the administration of the radiopharmaceutical given for diagnostic purposes?
What compliance and billing challenges can arise when multiple hospital departments perform laboratory testing, particularly with point-of-care testing (POCT)? In this regard, do you have any insight into billing modifier 91?
Subscribe to receive our News, Insights, and Compliance Question of the Week articles delivered right to your inbox.




CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24